As with a fermented food like kombucha, slight natural variations are normal and to be expected in a product such as CBD oil because it is made from living plants. Changes in the weather, soil, and water can all impact the biology of the source material. While we verify Certificates of Analysis (and take many other criteria into consideration during our review process), even the most reputable five-star companies have no way to control for every variable in this organic process.
CBD interacts with the body through the endogenous cannabinoid system (ECS) or endocannabinoid system. First discovered in the late 1980’s, the endocannabinoid system regulates the body’s homeostasis, or general state of balance, impacting such functions as mood, sleep, appetite, hormone regulation, and pain and immune response. Like an acrobat on a highwire, as the environment around us impacts our normal balance, the endocannabinoid system “corrects” by mediating our body’s reaction to keep us level.
It sounds like the title of a children’s book, but like so much else that you learned in kindergarten, it’s true. Everyone’s body is different – but everyone’s endocannabinoid system is really unique. For reasons we don’t fully understand, receptors in the endocannabinoid system don’t respond predictably to cannabinoids from person to person. This lack of a predictable response makes standard dosing tricky.
Hemp allows farmers to build a livelihood from a crop that’s both good for the environment and the growers themselves. Hemp puts back nitrogen into the soil. Cotton, on the other hand, can deplete the land’s nutrients, especially if not rotated with other crops. Unlike cotton which produces shorter fibers, hemp, though brittle when dry, thrives when it’s wet, explains Derek Thomas, co-founder of Hemp Blue, a LA-based startup producing hemp-based jeans, jackets, and shirts. The long, wet fibers don’t break, but actually grow in strength, he says. Hemp’s longer, wet fibers have greater durability than cotton, which has short fibers that need to be spun and woven.
Preliminary research indicates that cannabidiol may reduce adverse effects of THC, particularly those causing intoxication and sedation, but only at high doses. Safety studies of cannabidiol showed it is well-tolerated, but may cause tiredness, diarrhea, or changes in appetite as common adverse effects. Epidiolex documentation lists sleepiness, insomnia and poor quality sleep, decreased appetite, diarrhea, and fatigue.
Last year, the National Academies of Sciences, Engineering and Medicine released a nearly 500-page report on the health effects of cannabis and cannabinoids. A committee of 16 experts from a variety of scientific and medical fields analyzed the available evidence — more than 10,000 scientific abstracts in all. Because so few studies examine the effects of CBD on its own, the panel did not issue any findings about CBD specifically, but it did reach some conclusions about cannabis and cannabinoids more generally. The researchers determined that there is “conclusive or substantial evidence” supporting the use of cannabis or cannabinoids for chronic pain in adults, multiple sclerosis-related spasticity (a kind of stiffness and muscle spasms), and chemotherapy-induced nausea and vomiting. The committee also found “moderate” evidence that cannabis or cannabinoids can reduce sleep disturbances in people with obstructive sleep apnea, fibromyalgia, chronic pain and multiple sclerosis, as well as “limited” evidence that these substances can improve symptoms of Tourette’s syndrome, increase appetite and stem weight loss in people with HIV/AIDs, and improve symptoms of PTSD and anxiety.
Unfortunately due to strict FDA regulations I am unable to make claims on our products based on your specific needs, I can however say that CBD is a natural anti-inflammatory and could assist. I can also share our top selling products in each category. Please view the links below:http://cbdoilreview.org/product/elixinol-cbd-oil-extract-x-pen-1000mg/http://cbdoilreview.org/product/endoca-hemp-oil-drops-1500mg/http://cbdoilreview.org/product/elixinol-hemp-oil-drops-regular-300mg/http://cbdoilreview.org/product/elixinol-cbd-hemp-oil-capsules-900mg/https://cbdoilreview.org/product/vape-bright-starter-pack-200-mg/This is also a great link to some pages that you may find helpful https://cbdoilreview.org/cbd-cannabidiol/
Cannabis, especially the cannabinoid CBD, has also demonstrated its abilities as a powerful anti-convulsant. This property is what accounts for cannabis’ ability to reduce the severity and frequency of seizures, especially for people with epilepsy. In the United States, epilepsy is the most widely adopted qualifying condition for medical cannabis use, especially for children.
The Montana Department of Agriculture is not responsible for a pilot participant’s business plan or activities and will not be a mediator between pilot participants and any business associates or partners. We encourage interested individuals to contact a hemp trade association to learn more about marketing opportunities, such as the Hemp Industries Association or the National Hemp Association.
Also high in fiber, hemp seeds are more digestible than any other high-protein food, including meat, cheese, eggs, human milk, or cows’ milk. They’re high in antioxidants, and minerals like iron, zinc and copper as well as calcium, magnesium, potassium, carotene, thiamin (vitamin B1), riboflavin (vitamin B2), vitamin B6 and vitamin E. If that’s not enough, there’s also chlorophyll, sulfur, phosphorus, phospholipids, and phytosterols.
CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer. In this experimental system, azoxymethane increased premalignant and malignant lesions in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In in vitro experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation. In a subsequent study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors.
Despite the fact that marijuana remains illegal at the federal level, companies like HempMedsPx claim their CBD products are legal in all 50 states. According to a legal opinion written by Medical Marijuana, Inc.’s attorney and submitted to the New Republic, “HempMedsPx’s CBD hemp oil, containing naturally occurring CBD and miniscule amount of THC, is exempted from the definition of marijuana, is not a controlled substance, complies with the Controlled Substances Act, and is legal on the federal level.” The opinion is based in large part on a 2004 court ruling which allowed the importation of hemp food products derived from the mature stalks of cannabis plants.
The most valid claims to environmental friendliness of hemp are with respect to agricultural biocides (pesticides, fungicides, herbicides). Cannabis sativa is known to be exceptionally resistant to pests (Fig. 51), although, the degree of immunity to attacking organisms has been greatly exaggerated, with several insects and fungi specializing on hemp. Despite this, use of pesticides and fungicides on hemp is usually unnecessary, although introduction of hemp to regions should be expected to generate local problems. Cannabis sativa is also relatively resistant to weeds, and so usually requires relatively little herbicide. Fields intended for hemp use are still frequently normally cleared of weeds using herbicides, but so long as hemp is thickly seeded (as is always done when hemp is grown for fiber), the rapidly developing young plants normally shade out competing weeds.
The potential benefits of medicinal Cannabis for people living with cancer include antiemetic effects, appetite stimulation, pain relief, and improved sleep. Although few relevant surveys of practice patterns exist, it appears that physicians caring for cancer patients in the United States who recommend medicinal Cannabis do so predominantly for symptom management. A growing number of pediatric patients are seeking symptom relief with Cannabis or cannabinoid treatment, although studies are limited. The American Academy of Pediatrics has not endorsed Cannabis and cannabinoid use because of concerns about brain development.
Support for legalization has steadily grown over the last several years. Today, medical marijuana is legal in 23 states and the District of Columbia. And even federal officials have begun to soften their stances. Last fall, outgoing Attorney General Eric Holder signaled his support for removing marijuana from the list of Schedule I narcotics. “I think it’s certainly a question we need to ask ourselves, whether or not marijuana is as serious of a drug as heroin,” Holder said. This summer, Chuck Rosenberg, the acting administrator of the U.S. Drug Enforcement Administration, acknowledged that marijuana is not as dangerous as other Schedule I drugs and announced his agents would not be prioritizing marijuana enforcement. Still, as long as marijuana remains illegal under federal law, the haphazard system in which it is studied, produced, and distributed will remain, and Americans will not be able to take full advantage of its medicinal properties.
Following an 1836–1840 travel in North Africa and the Middle East, French physician Jacques-Joseph Moreau wrote on the psychological effects of cannabis use; Moreau was a member of Paris' Club des Hashischins (founded in 1844). In 1842, Irish physician William Brooke O'Shaughnessy, who had studied the drug while working as a medical officer in Bengal with the East India company, brought a quantity of cannabis with him on his return to Britain, provoking renewed interest in the West. Examples of classic literature of the period featuring cannabis include Les paradis artificiels (1860) by Charles Baudelaire and The Hasheesh Eater (1857) by Fitz Hugh Ludlow.
There are also other difficulties in researching the effects of cannabis. Many people who smoke cannabis also smoke tobacco. This causes confounding factors, where questions arise as to whether the tobacco, the cannabis, or both that have caused a cancer. Another difficulty researchers have is in recruiting people who smoke cannabis into studies. Because cannabis is an illegal drug in many countries, people may be reluctant to take part in research, and if they do agree to take part, they may not say how much cannabis they actually smoke.
Cannabis is believed to be an aggravating factor in rare cases of arteritis, a serious condition that in some cases leads to amputation. Because 97% of case-reports also smoked tobacco, a formal association with cannabis could not be made. If cannabis arteritis turns out to be a distinct clinical entity, it might be the consequence of vasoconstrictor activity observed from delta-8-THC and delta-9-THC. Other serious cardiovascular events including myocardial infarction, stroke, sudden cardiac death, and cardiomyopathy have been reported to be temporally associated with cannabis use. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. These putative effects can be taken in context of a wide range of cardiovascular phenomena regulated by the endocannabinoid system and an overall role of cannabis in causing decreased peripheral resistance and increased cardiac output, which potentially could pose a threat to those with cardiovascular disease. There is some evidence from case reports that cannabis use may provoke fatal cardiovascular events in young people who have not been diagnosed with cardiovascular disease. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
Pain management improves a patient’s quality of life throughout all stages of cancer. Through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced analgesia have been analyzed.[Level of evidence:1iC] The CB1 receptor is found in the central nervous system (CNS) and in peripheral nerve terminals. CB2 receptors are located mainly in peripheral tissue and are expressed in only low amounts in the CNS. Whereas only CB1 agonists exert analgesic activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.[48,49]